Publications and Presentations

Check out our publications and poster presentations.

April 2022

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Clinical Cancer Research

April 2022

Identification of novel VPS4A inhibitors for the treatment of VPS4B-deleted cancers

American Association for Cancer Research

November 2021

The glutaminase inhibitor telaglenastat enhances the antitumor activity of signal transduction inhibitors everolimus and cabozantinib in models of renal cell carcinoma.

PLOS One

November 2021

Phase I Study of Novel SYK Inhibitor TAK-659 in Combination with R-CHOP for Front-Line Treatment of High Risk Diffuse Large B-Cell Lymphoma

American Society of Hematology

November 2021

A Phase 1b Randomized, Double-blind, Placebo-controlled, Dose Escalation Trial of CB-280, an Arginase Inhibitor, in Patients With Cystic Fibrosis

North American Cystic Fibrosis Conference

Our Pipeline

We are focused on novel treatments for
cancer and other life-threatening diseases.

View Our Pipeline